Monte Rosa Therapeutics Receives FDA Clearance for MRT-8102, First NEK7-Targeted Molecular Glue Degrader for Inflammatory Diseases
核心洞察
Monte Rosa Therapeutics received FDA clearance for its Investigational New Drug application for MRT-8102, a NEK7 (搜索)-directed molecular glue degrader targeting inflammatory diseases (搜索) driven by NLRP3 (搜索) inflammasome and IL-1β (搜索) dysregulation.
MRT-8102 demonstrated nanomolar-level NEK7 (搜索) degradation with no off-target activity and achieved near-complete inhibition of downstream inflammatory markers in non-human primate studies.
The company plans to initiate a Phase 1 healthy volunteer study in the coming weeks, with clinical results including safety, pharmacokinetics, and pharmacodynamic data expected in the first half of 2026.
Monte Rosa Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for MRT-8102, a NEK7 (搜索)-directed molecular glue degrader designed to treat inflammatory diseases (搜索) driven by the NLRP3 (搜索) inflammasome and IL-1β (搜索). The clinical-stage biotechnology company plans to initiate a Phase 1 study in the coming weeks, with initial results expected in the first half of 2026.
MRT-8102 represents the first clinical-stage molecular glue degrader that selectively targets NEK7 (搜索), positioning it to address multiple inflammatory conditions including cardio-immunology, rheumatology, and respiratory indications. According to CEO Markus Warmuth, M.D., the compound could provide "a highly differentiated clinical profile compared to IL-1 antibodies and NLRP3 (搜索) inhibitors in development based on its potency, selectivity, and long-lasting pharmacodynamics."
Preclinical Efficacy and Safety Profile
Preclinical studies demonstrated MRT-8102's nanomolar-level degradation of NEK7 (搜索) in vitro with no observed off-target activity, including against related NEK family proteins. In non-human primate studies, oral administration resulted in near-complete inhibition of downstream inflammatory markers in ex vivo stimulation assays and improvements in pathological measures in inflammatory disease models.
The compound showed therapeutic potential in a rabbit gout (搜索) model, where daily oral dosing reduced pathogenic effects including joint swelling and histopathology scores. Preclinical GLP toxicology studies revealed a considerable safety margin, with greater than 200-fold exposure margin over the projected human efficacious dose in both rats and non-human primates.
Clinical Development Strategy
The upcoming Phase 1 study will evaluate safety, pharmacokinetics, NEK7 (搜索) protein degradation, and key downstream pharmacodynamic markers in healthy volunteers. As part of the study design, Monte Rosa plans to establish initial proof-of-concept for cardio-immunology indications by evaluating changes in C-reactive protein and other inflammatory markers in subjects with elevated CRP levels.
NEK7 as a Therapeutic Target
NEK7 (搜索) has been shown to be required for NLRP3 (搜索) inflammasome assembly, activation, and IL-1β (搜索) release both in vitro and in vivo. Aberrant NLRP3 inflammasome activation and subsequent release of active IL-1β and interleukin-18 has been implicated in multiple inflammatory disorders, including cardiovascular disease (搜索), gout (搜索), osteoarthritis (搜索), neurologic disorders such as Parkinson's and Alzheimer's diseases, and metabolic disorders.
In non-human primate models, MRT-8102 demonstrated potent, selective, and durable NEK7 (搜索) degradation, resulting in near-complete reductions of IL-1β (搜索) and caspase-1 following ex vivo stimulation of whole blood.
Pipeline Expansion
Beyond MRT-8102, Monte Rosa is advancing a second-generation NEK7 (搜索) program with enhanced central nervous system penetration, with an IND submission expected in 2026. The company retains full worldwide rights to MRT-8102 and its second-generation CNS-optimized NEK7 molecular glue degraders.
This IND clearance marks Monte Rosa's second inflammatory and immunology indication following MRT-6160, a VAV1 (搜索)-directed molecular glue degrader, expanding the company's clinical portfolio in this therapeutic area.